Benefit-Risk assessment of vaccines, the perspective of a European regulatory agency
|
|
- Daisy Hunter
- 5 years ago
- Views:
Transcription
1 Perspective on Benefit-Risk Decision-making in Vaccinology Les Pensières Fondation Mérieux Conference Center June 2014 Benefit-Risk assessment of vaccines, the perspective of a European regulatory agency Christoph Conrad Paul-Ehrlich-Institut Paul-Ehrlich-Strasse Langen GERMANY +49 (0) (0) christoph.conrad@pei.de Homepage:
2 Benefit-Risk evaluations are at the heart of decisionmaking in the regulation of medicines clinical development licensing postmarketing 2
3 AMG (Medicinal Products Act) 4: Definition (28) The risk-benefit balance is an assessment of the positive therapeutic effects of the medicinal product in relationship to the risk referred to in sub-section 27 letter a, and in the case of medicinal products intended for use in animals, also referred to in sub-section 27 letter b. (28) Das Nutzen-Risiko-Verhältnis umfasst eine Bewertung der positiven therapeutischen Wirkungen des Arzneimittels im Verhältnis zu dem Risiko nach Absatz 27 Buchstabe a, bei zur Anwendung bei Tieren bestimmten Arzneimitteln auch nach Absatz 27 Buchstabe b. 3
4 Risk: Definition AMG (Medicinal Products Act) 4 (27) A risk linked to the use of a medicinal product is: a) any risk to patients health or public health linked to the quality, safety or efficacy of the medicinal product and, in the case of medicinal products intended for use in animals, any risk to human or animal health, b) any risk of adverse effects on the environment. (27) Ein mit der Anwendung des Arzneimittels verbundenes Risiko ist a) jedes Risiko im Zusammenhang mit der Qualität, Sicherheit oder Wirksamkeit des Arzneimittels für die Gesundheit der Patienten oder die öffentliche Gesundheit, bei zur Anwendung bei Tieren bestimmten Arzneimitteln für die Gesundheit von Mensch oder Tier, b) jedes Risiko unerwünschter Auswirkungen auf die Umwelt. 4
5 AMG (Medicinal Products Act) 40: Clinical Trials the foreseeable risks and inconveniences are medically justifiable, compared with the benefit for the person on whom the clinical trial is to be conducted (person concerned), and the anticipated significance of the medicinal product for medical science,...die vorhersehbaren Risiken und Nachteile gegenüber dem Nutzen für die Person, bei der sie durchgeführt werden soll (betroffene Person), und der voraussichtlichen Bedeutung des Arzneimittels für die Heilkunde ärztlich vertretbar sind,... 5
6 Benefit-risk balance Both benefits and risks are balanced against each other, i.e. judged in the relative importance Inherently difficult because very different outcomes/effects may have to be balanced Moving target in clinical development Benefit-risk evaluation is not a static but a dynamic process Benefit-risk balance changes with accumulating data Benefit-risk balance changes with different stage of development and may change also after marketing authorization Remark: The term Benefit-risk-ratio is not meaningful 6
7 Benefit-risk balance postmarketing Example: Benefit-risk balance in case of a new finding of a potential adventitious agent previously unrecognized 7
8 Knowns and unknowns There are known knowns. These are things we know that we know. There are known unknowns. That is to say, there are things that we now know we don t know. But there are also unknown unknowns. These are things we do not know we don t know. Donald Rumsfeld Known knowns: favorable or unfavorable effects Known unknowns: uncertainties Unknown unknowns: 8
9 Background Porcine circovirus DNA in rotavirus vaccines in 2010 New technologies may detect agents that previous methods were not capable of Recommendation from ECBS and ICDRA: WHO to assist countries in developing a risk assessment process subsequent to marketing authorization A broad regulatory framework exist pre-licensure But a few aspects associated with findings, discovered subsequent to marketing authorization are not well defined, in the sense of regulatory actions and decision-making 9
10 Scope and Purpose To provide an overview of the principles related to the scientific assessment of risk with any new finding of a potential adventitious agent in an already registered biological product. To assist regulators in the considerations they might include during the evaluation and decision-making process. It does not cover: Risk assessments performed by the manufacturer Guidance on the decisions taken by health care officials (NITAGs) Guidance on GMP compliance and subsequent decisions/actions 10
11 Regulatory risk evaluation process 11
12 Re-evaluation & New Benefit / Risk Re-evaluation of: Quality / non-clinical / clinical data Post-marketing data (phase IV, pharmacovigilance) Communication with the Inspectorate New benefit/risk assessment Process which largely depends on: Type of adventitious Agent Type of product and Indication Communication with public health officials (NITAGs) 12
13 Outcome of benefit risk project in licensing (EMA) B/R are balanced intuitively; a matter of judgement Distinct separation of the B/R elements to: Favourable effects Unfavourable effects Uncertainty of favourable effects Uncertainty of unfavourable effects 13
14 Example (hypothetical) Benefits Risks N ame Descript ion Unit Placebo 300 mg Progressionfree survival Hazard Ratio Progressionfree survival (median) Objective Response (RECIST) Diarrhoea CTC3 Grade 3-4 QTc related events CTC 3 Grade 3-4 Infections CTC 3 Grade 3-4 Date of randomization to the date of objective progression or death Date of randomization to the date of objective progression or death (Weibull model) Proportion of complete or partial responders (at least a 30% decrease in the sum of the longest diameter from baseline) Increase of 7 stools per day over baseline; incontinence; IV fluids 24 hrs; hospitalization; QTc >0.50 second; life threatening signs or symptoms (e.g., arrhythmia, CHF, hypotension, shock syncope); Torsade de pointes IV antibiotic, antifungal, or antiviral intervention indicated; ; Lifethreatening consequences (e.g., septic shock, hypotension, acidosis, necrosis) unitless Only a very low number of patients with definite RET negative status at baseline months % Uncertainties Reference in the text From Weibull model distributional assumptions probably do not hold Not a good surrogate. May provide some symptom relief (assumed) Major Objection No. 1, Discussion on Clinical Efficacy (page 44) % % Duration of follow up in the pivotal study is quite short with regard to the need for long duration of treatment and therefore the risk of developing further major Cardiac SAEs including Torsades de pointe. Could the risk be underestimated? How well can oncologists monitor in clinical practice? Major Objection No. 2, Discussion on Clinical Safety (page 65), Scientific Advisory Group answers to CHMP See RMP % Discussion on Clinical Safety (page 66) 14
15 B/R assessment methodology in case of Porcine circovirus DNA in rotavirus vaccines an example Based on EMA Benefit-Risk Methodology Project CHMP assessment report template Four-fold qualitative model Favourable effects Uncertainty of favourable effects Unfavourable effects Uncertainty of unfavourable effects 15
16 Clinical benefits of Rotavirus Vaccines are established Recognized medical need In clinical trials: Demonstrated protection against RV gastroenteritis (GE) Across circulating RV strains In various settings (epidemiologic, socio-economic, ) Demonstrated impact on reduction of hospitalisations related to RVGE Safe and immunogenic in special populations (HIV+, preterm) Persistence of protection over 3 years Effectiveness and impact studies (including reduction of diarrhearelated mortality) Confidence on benefit has increased since license (decreased uncertainty of favourable effects) 16
17 B/R assessment methodology in case of Porcine circovirus DNA in rotavirus vaccines an example Based on EMA Benefit-Risk Methodology Project CHMP assessment report template Four-fold qualitative model Favourable effects Uncertainty of favourable effects Unfavourable effects Uncertainty of unfavourable effects 17
18 Safety Profile of Rotavirus Vaccine is Similar to Placebo Serious adverse events occurred at similar rates compared to placebo, significantly fewer SAEs associated with GE disease in Vaccine vs placebo (pooled studies) Safety meta-analysis: Solicited adverse events occurred at similar rates in Vaccine and placebo recipients Unsolicited adverse events more frequently observed in Vaccine recipients are diarrhea, abdominal pain, flatulence, dermatitis and irritability No increased risk of intussusception compared to placebo: controlled safety study 18
19 B/R assessment methodology in case of Porcine circovirus DNA in rotavirus vaccines an example Based on EMA Benefit-Risk Methodology Project CHMP assessment report template Four-fold qualitative model Favourable effects Uncertainty of favourable effects Unfavourable effects Uncertainty of unfavourable effects 19
20 Potential unforeseen risks linked to the presence of PCV1 in Rotavirus Vaccine Fact: PCV1 DNA has been found in Rotavirus Vaccine Risk of PCV1 being pathogenic in humans Fact: no AEs typical of PCV1 have been seen in safety database Risk of PCV1 being infectious in humans Risk of safety issue from PCV-1 in Risk of PCV1 replicative virions in vaccine Risk of PCV1 replication in human gut Infants may react differently to PCV1 infection Fact: ingestion of PCV1 is common in adults and older children, although not pathogenic 20
21 Risk of PCV-1 being infectious in humans Clinical sample testing from Vaccine recipients Currently available data do not suggest occurrence of PCV-1 infection PCV has been reported as not infecting humans, although the exposure level from food is thought to be high (Li et al., 2010) Absence of anti-pcv-1 Abs in human serum in most reports (Allan et al. (1994),Todd et al. (2001), Tischer et al. (1995)) No evidence of PCV infection in patients receiving xenotransplants of pig tissue (Garkavenko et al., 2004) No evidence of circoviruses in a range of human tissues from >168 immunocompromised adults (presumed dietary exposure through meat) (Hattermann et al., 2004b) 21
22 Risk of PCV-1 being pathogenic in humans 5. Adverse reactions in the short-medium term? No signals in clinical and post-marketing data No evidence of PCV-related pathogenicity in humans exposed to pork meat or swine => LOW PROBABILITY 6. Could PCV-1 DNA integrate into the genome of vaccine recipients? No reported evidence of PCV integration into host DNA simple, circular genome makes this highly unlikely (Peden 2001) => LOW PROBABILITY 7. Could PCV-1 cause long-term health problems in vaccine recipients (i.e. infants)? Not pathogenic in children from pork-consuming age No safety signal within first 2-3 years post-vaccination => LOW PROBABILITY 22
23 Exposure to PCV-1 through other sources PCV-1 detected in commercial products including veterinary vaccines: a common event PCV1 DNA detected in commercial pepsin but no infectivity in inoculated PK-15 cells or in inoculated pigs (Fenaux et al., 2004) PCV-1 DNA detected in 11% (2/18) of the commercial porcine vaccines on the market (Quintana et al., 2005) PCV frequent in pork products (Li et al., 2010) Exposure of infants to PCV-1 not documented, however potential sources of exposure include products from porcine origin and/or products that use porcine extracts in the manufacturing cycle, examples: Powder milk (use of food grade pork trypsin in manufacturing) Surfactants from pork origin used to treat neonatal respiratory distress syndrome (RDS) Pork gelatin as food additive Pancreatic Enzyme Replacement Therapy: used in the treatment of exocrine pancreatic insufficiency. Extracted from pigs glands 23
24 Semi-quantitative risk assessment Probability of impact Size of impact Probability of intact virus present in Rotavirus Vaccine Probability of it being infectious in humans Probability of PCV1 being pathogenic in humans Overall probability of impact Likelihood of impact not seen with 3 year safety data Likelihood of impact not seen in children from porkconsuming age Overall size of impact high low low low low low low Probability of impact * Size of impact = Risk low 24
25 Rotavirus Vaccine Benefit/Risk is Positive remains Presence of PCV-1 RV leading cause of severe childhood diarrhea Vaccination only known effective preventative strategy Widespread use of rotavirus vaccines can prevent about 2 million deaths over next decade (NEJM 2010:362;4) Safety data from clinical trials and post-marketing reflects presence of PCV Potential unforeseen risks linked to PCV are low Benefit/risk for Rotavirus vaccine remains favorable 25
26 Acknowledgements Paul Ehrlich Institut Dr. Jan Müller-Berghaus Dr. Michael Pfleiderer 26
27 Thank you for your attention
Questions and answers relating to finding of DNA fragments of a porcine circovirus in Rotarix vaccine
21 April 2010 Questions and answers relating to finding of DNA fragments of a porcine circovirus in Rotarix vaccine What is the issue? A United States academic research team discovered the presence of
More informationDealing with Post-market Issues: PCV Case Study
Dealing with Post-market Issues: PCV Case Study CASE STUDY: Adventitious agent in raw material ISSUE: Presence of porcine circovirus (PCV-1) DNA detected in marketed rotavirus vaccine by an independent
More informationRegulatory requirements for universal flu vaccines Perspective from the EU regulators
Regulatory requirements for universal flu vaccines Perspective from the EU regulators EDUFLUVAC workshop 12-14 June Marco Cavaleri Head of Anti-infectives and Vaccines Scientific & Regulatory Management
More informationBenefit Risk Assessment. Patrick Salmon Eurordis Summer School 8 th June, 2016
Benefit Risk Assessment Patrick Salmon Eurordis Summer School 8 th June, 2016 1 How do we reach a positive opinion? Benefit. What s good Risks. What s not so good 2 Benefit Risk Balance benefits risks
More informationBenefit-risk methodology project: work package 4 report: benefit-risk tools and processes
Lawrence Phillips, et al. : work package 4 report: benefit-risk tools and processes Report (Published version) Original citation: Phillips, Lawrence D., et al., : work package 4 report: benefit-risk tools
More informationVaccine Efficacy, Effectiveness and Impact. G. HANQUET, KCE, 9 September 2017
Vaccine Efficacy, Effectiveness and Impact G. HANQUET, KCE, 9 September 2017 RvB - CA, 16/09/2014 Outline The confusion Vaccine effects Methodologies Challenges Implications for decision making 2 Life
More informationImproving new drug development for paediatric cancer: the EMA and PDCO vision
Dr. Dirk Mentzer, MD, PhD Consultant General Paediatrics Head of Pharmacovigilance unit Chair of PDCO at EMA Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines, Germany Disclaimer The
More informationProposed 1 st IS for Hepatitis E Virus RNA WHO/BS/
www.pei.de Proposed 1 st IS for Hepatitis E Virus RNA WHO/BS/09.2126 S. Baylis, Division of Virology, Paul-Ehrlich-Institut, Langen, Germany SoGAT XXII 14 th -15 th April 2011, Rome, Italy Presented at:
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution, 1 dose (1 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID 50 PHARMACEUTICAL
More informationRotarix TM. Rotavirus vaccine
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain* of the G1P[8] type: not less than 10 6.0 CCID 50 *Produced
More informationClinical trials: Role of a DSMB
Clinical trials: Role of a DSMB 15 th Advanced Course of Vaccinology May 15, 2014 Penny M. Heaton, MD Director of Vaccine Development Vaccine Development: Catalyze development of low cost vaccines that
More informationComments from PlasticsEurope
Polycarbonate/Bisphenol A Group Follow-up Meeting on the Web-Based Public Consulting on Bisphenol A Brussels, April 23 2014 Comments from PlasticsEurope Dieter Beyer Representing the Polycarbonate/Bisphenol
More informationNivolumab Addendum to Commission A
IQWiG Reports Commission No. A15-58 Nivolumab Addendum to Commission A15-32 1 Addendum Commission:A15-58 Version: 1.0 Status: 13 January 2016 1 Translation of addendum A15-58 Nivolumab Addendum zum Auftrag
More informationUpdates on Rotasiil development
Updates on Rotasiil development 13 th International Rotavirus Symposium Minsk, Belarus 30 August 2018 Dr Sajjad Desai MD Serum Institute of India Pvt Limited, Pune Rotasiil Bovine-human reassortant strains
More informationInstruction to implement measures for risk minimisation in using HIV-1 NAT test systems
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: The marketing authorisation holders of cellular blood products and fresh frozen plasma and the holders of authorisations for stem cell preparations
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objective: Primary Outcome/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationGlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT. Rotarix TM 1 WHO Package insert
GlaxoSmithKline Biologicals Rotarix WHO PACKAGE INSERT Rotarix TM 1 WHO Package insert GlaxoSmithKline Biologicals Rotarix Method of administration Rotarix is for oral use only. ROTARIX SHOULD UNDER NO
More informationExecutive Summary. Evaluation of the therapeutic benefits and harms of exenatide 1. IQWiG Reports - Commission No. A05-23
IQWiG Reports - Commission No. A05-23 Evaluation of the therapeutic benefits and harms of exenatide 1 Executive Summary 1 Translation of the executive summary of the final report Bewertung des therapeutischen
More informationRotarix TM. Rotavirus vaccine. 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain
Rotarix TM Rotavirus vaccine QUALITATIVE AND QUANTITATIVE COMPOSITION 1 dose (1.5 ml) contains: Live attenuated human rotavirus RIX4414 strain not less than 10 6.0 CCID50 PHARMACEUTICAL FORM Oral suspension.
More informationUpdate on Pentavalent Human-Bovine Rotavirus Vaccine. Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014
Update on Pentavalent Human-Bovine Rotavirus Vaccine Michelle Goveia, MD, MPH Medical Director MSD Vaccines India, September 2014 Outline Characteristics of RotaTeq and its worldwide use Recent data evaluating
More informationFecal shedding of rotavirus vaccine in premature babies in the neonatal unit
Fecal shedding of rotavirus vaccine in premature babies in the neonatal unit Dr. Manish Sadarangani Director, Vaccine Evaluation Center, BC Children s Hospital Research Institute Assistant Professor, Division
More informationNorthwestern Health Unit
Northwestern Health Unit www.nwhu.on.ca 210 First Street North Kenora Ontario P9N 2K4 1-800-830-5978 July 26, 2018 Re: Ontario Rotavirus Immunization Program - Transitioning to RotaTeq (Rot-5) pentavalent
More informationM. hyo. M. hyo. M. hyo. Single injection. Double protection. Ready-to-use protection against both PCV2 and M. hyo. It s easy. It works.
M. hyo P C V 2 P C V 2 M. hyo M. hyo P C V 2 Single injection. Double protection. Single injection. Double protection. Ready-to-use protection against both PCV2 and M. hyo. PCV M Hyo It s easy. It works.
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 26/09/2017 Labelling. 22/09/2017 n/a
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationCommission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 19/10/2018 n/a. 21/05/2018 SmPC, Annex II, Labelling
Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected
More informationVIRAL GASTRO-ENTERITIS
VIRAL GASTRO-ENTERITIS Dr Esam Ibraheem Azhar (BSc, MSc, Ph.D Molecular Medical Virology) Asst. Prof. Medical Laboratory Technology Department ١ Gastroenteritis Introduction (1) Paediatric diarrhoea remains
More informationVeterinary medicines highlights 2017
Veterinary medicines highlights 2017 Authorisation of new medicines Overview of the key figures on the European Medicines Agency s (EMA) recommendations for the authorisation of new veterinary medicines
More informationA rotavirus immunisation programme was introduced into the routine childhood immunisation programme from 1 July 2013 for infants aged 2 and 3 months.
A rotavirus immunisation programme was introduced into the routine childhood immunisation programme from 1 July 2013 for infants aged 2 and 3 months. Rotavirus is a very common and potentially serious
More informationSolution for Oral Administration RotaTeq (rotavirus vaccine, live, oral, pentavalent, MSD)
Solution for Oral Administration RotaTeq (rotavirus vaccine, live, oral, pentavalent, MSD) I. THERAPEUTIC CLASS RotaTeq is a live, oral liquid pentavalent vaccine which protects against rotavirus gastroenteritis.
More informationAssessing Vaccine Safety Post Licensure. Neal A. Halsey Johns Hopkins University
Assessing Vaccine Safety Post Licensure Neal A. Halsey Johns Hopkins University Inactivated Respiratory Syncytial Virus Vaccine: 1960 s Formalin inactivated Administered to infants Minimal reactions Induced
More informationGSK Medicine: Study No.: Title: Rationale: Objectives: Indication: Study Investigators/ Centres: Research Methods: Data Source Study Design
GSK Medicine: Rotarix (HRV1): GlaxoSmithKline (GSK) Biologicals oral live attenuated human rotavirus vaccine Study No.: 114910 (EPI-ROTA-025 VE AU DB) Title: A study on the impact of rotavirus vaccination
More informationRotavirus serotype surveillance: Results and experiences in Tanzania. Adolfine Hokororo. KPA Vaccinology Symposium- 29 th April
Rotavirus serotype surveillance: Results and experiences in Tanzania Adolfine Hokororo KPA Vaccinology Symposium- 29 th April 2016 1 outline 1. Introduction-burden of RVGE 2. goals of RVGE sentinel surveillance
More informationDeveloping a Target Product Profile for a Preventive HIV Vaccine
Developing a Target Product Profile for a Preventive HIV Vaccine Topics to be Covered Overview of TPPs What are they? What is the purpose and benefit of using a TPP? What is usually in a TPP? What are
More informationPost Licensure Communication on Vaccine Safety among Regulator, Industry and Stakeholder
Post Licensure Communication on Vaccine Safety among Regulator, Industry and Stakeholder Lucky S Slamet DCVMN International Annual General Meeting, New Delhi, India, 8-10 July 2014 1 Disclaimer The information
More informationGlobal Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting
Global Advisory Committee on Vaccine Safety (GACVS) Report from the June 2017 meeting Topics discussed in June Safety monitoring of the RTS,S vaccine pilot implementation programme Safety update of BCG
More informationRotavirus: WHO Global Recommendations, Policy, and Surveillance
Rotavirus: WHO Global Recommendations, Policy, and Surveillance 9 th International Rotavirus Symposium 2 August 2010 Mary Agócs, MD, MSc Department of Immunization, Vaccines & Biologicals From 1999 2009:
More informationVaccination with RotaTeq. Questions & Answers for Immunization Providers
Vaccination with RotaTeq Questions & Answers for Immunization Providers Office of the Chief Medical Officer of Health Communicable Disease Control Branch June 2018 1. Why is a rotavirus vaccine program
More informationRotavirus. Factsheet for parents. Immunisation for babies up to a year old
Rotavirus Factsheet for parents This factsheet describes the rotavirus infection and the vaccine that protects against it. It also provides the background to the development and introduction of the vaccination
More informationReflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular and metabolic diseases Draft
1 2 3 21 May 2015 EMA/CHMP/50549/2015 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Reflection paper on assessment of cardiovascular risk of medicinal products for the treatment of cardiovascular
More informationSummary 1. Comparative effectiveness of ataluren Study 007
Cost-effectiveness of Ataluren (Transarna TM ) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophy gene in ambulatory patients aged 5 years and older The
More informationUncertainties in Dietary Exposure Analysis A Challenge to Be Addressed
Uncertainties in Dietary Exposure Analysis A Challenge to Be Addressed Dr David Tennant Food Chemical Risk Analysis, UK Conflict of interest regarding this presentation: I wish to declare a potential conflict
More informationNHS public health functions agreement Service specification No.5 Rotavirus immunisation programme
NHS public health functions agreement 2018-19 Service specification No.5 Rotavirus immunisation programme Classification: official 1 NHS public health functions agreement 2018-19 Service specification
More informationSafeguarding public health Subgroup Analyses: Important, Infuriating and Intractable
Safeguarding public health Subgroup Analyses: Important, Infuriating and Intractable The views expressed herein are not necessarily those of MHRA, EMA, EMA committees or their working parties. Rob Hemmings
More informationKurse Epidemiology & Public Health
Der Titel des PDFs ist in der Localize-Variable title_pdf_standard abgelegt. Manuelle Zeilenumbrüche können mit dem Pipe-Symbol gesetzt werden. Kurse Epidemiology & Public Health Coordinator: Mrs. Catherine
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationReflection paper on assessment of cardiovascular safety profile of medicinal products
25 February 2016 EMA/CHMP/50549/2015 Committee for Medicinal Products for Human Use (CHMP) Reflection paper on assessment of cardiovascular safety profile of medicinal products Draft agreed by Cardiovascular
More informationKEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE
RNI Conseil 2017 Tous droits réservés Toute reproduction interdite sans l'autorisation de l'auteur. KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE Anne Laure TARDY, PhD
More informationSafety of Paediatric CTs. A view of the PDCO
The role of Regulatory Agencies on Vaccine Safety Safety of Paediatric CTs A view of the PDCO Les Pensières, Fondation Mérieux Veyrier du Lac, March 2010 Dr Daniel Brasseur Belgian & European Agencies
More information2008 Public Status Report on the Implementation of the European Risk Management Strategy. Executive Summary
European Medicines Agency London, 17 March 2009 Doc. Ref. EMEA/43556/2009 2008 Status Report on the Implementation of the European Risk Management Strategy Executive Summary The European Risk Management
More informationAssessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation
Assessing the Safety of Vaccines at the FDA: Pre- and Post-Licensure Evaluation Karen Farizo, M.D. Office of Vaccines Research and Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationListeria monocytogenes Risk Assessment: Executive Summary
Listeria monocytogenes Assessment: Executive Summary FDA/Center for Food Safety and Applied Nutrition USDA/Food Safety and Inspection Service September 2003 Background The U.S. Department of Health and
More informationPublic Assessment Report. Scientific discussion MINOXIDIL AT/H/0638/ /DC. Date:
CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Alocutan 20 mg/ml Spray zur Anwendung auf der Haut, Lösung, Alocutan 50 mg/ml Spray zur Anwendung auf der Haut, Lösung MINOXIDIL
More informationOverview of comments received on Community herbal monograph on Rosmarinus officinalis L., aetheroleum (EMA/HMPC/235453/2009)
15 July 2010 EMA/HMPC/254083/2010 Committee on Herbal Medicinal Products (HMPC) Overview of comments received on Community herbal monograph on Rosmarinus officinalis L., aetheroleum Table 1: Organisations
More informationROTAVIRUS VACCINES FOR AUSTRALIAN CHILDREN: INFORMATION FOR GPS AND IMMUNISATION PROVIDERS
ROTAVIRUS VACCINES FOR AUSTRALIAN CHILDREN: INFORMATION FOR GPS AND IMMUNISATION PROVIDERS Summary Rotavirus is the most common cause of severe gastroenteritis in infants and young children, accounting
More informationU.S. Food & Drug Administration Center for Food Safety & Applied Nutrition Foodborne Pathogenic Microorganisms and Natural Toxins Handbook
U.S. Food & Drug Administration Center for Food Safety & Applied Nutrition Foodborne Pathogenic Microorganisms and Natural Toxins Handbook Salmonella spp. 1. Name of the Organism: Salmonella spp. Salmonella
More informationManaging cost considerations and access to technology for cost effective vaccine manufacture in developing countries.
Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rotarix powder and solvent for oral suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationRotavirus Vaccine: Questions and Answers for Health Care Providers
GOVERNMENT OF MANITOBA Department of Health, Seniors and Active Living Rotavirus Vaccine: Questions and Answers for Health Care Providers July 2017 Table of Contents Program Background, Rationale, and
More information9/11/2018. Rotavirus. Rotavirus. Rotavirus. First identified as a cause of diarrhea in 1973
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Rotavirus September 2018 Photographs and images included in this presentation are licensed solely for
More informationAnnex. Scientific conclusions and grounds for refusal presented by the European Medicines Agency
Annex Scientific conclusions and grounds for refusal presented by the European Medicines Agency Scientific conclusions and grounds for refusal presented by the European Medicines Agency Overall summary
More informationThe reassortants are propagated in Vero cells using standard tissue culture techniques in the absence of antifungal agents.
PRODUCT INFORMATION RotaTeq (rotavirus vaccine, live, oral, pentavalent, MSD) NAME OF THE MEDICINE Rotavirus vaccine live oral pentavalent DESCRIPTION RotaTeq is a live, oral pentavalent reassortant vaccine
More informationSecretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director
COUNCIL OF THE EUROPEAN UNION Brussels, 13 February 2014 (OR. en) 6438/14 COVER NOTE From: date of receipt: 3 February 2014 To: No. Cion doc.: PHARM 14 SAN 72 MI 161 COMPET 107 DELACT 29 Secretary-General
More informationPHARMACOVIGILANCE GLOSSARY
PHARMACOVIGILANCE GLOSSARY Section 1 Section 2 Section 3 Section 4 Definitions of terminology used for side effects Definitions of drug safety terms Definitions of risk terminology Definitions of general
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationCloudbreak. January Cidara Therapeutics
Cloudbreak January 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationCorrelates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations
Correlates of efficacy for human rotavirus vaccines Value of anti-rotavirus immunoglobulin A antibody concentrations Brigitte Cheuvart, Kathleen M. Neuzil, Duncan Steele, Nigel Cunliffe, Shabir A. Madhi,
More informationKombination von Checkpointinhibitoren beim malignen Melanom
Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom
More informationAssessing public health impact through vaccine probe analyses. Robert F. Breiman Emory Global Health Institute Emory University
Assessing public health impact through vaccine probe analyses Robert F. Breiman Emory Global Health Institute Emory University State of understanding the relative role of pathogens in major disease syndromes
More informationPROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT PROBIOTICS: WHAT ARE THEY, AND HOW DO THEY WORK? Karen Jensen, (Retired ND)
PROBIOTICS: WHO S WHO AND WHAT S WHAT IN THE GUT Karen Jensen, (Retired ND) Today many people are aware of the benefits of maintaining a healthy gut. As a result, probiotic use is becoming ever more popular.
More informationInformation for the use of medicines in the elderly
Information for the use of medicines in the elderly Geriatric Medicines Strategy EMA - Payer Community meeting Presented by Francesca Cerreta An agency of the European Union Population pyramid, EU-28,
More informationDecentralised Procedure. Public Assessment Report. Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC
Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Nurofen Immedia 200mg Weichkapseln Ibuprofen DE/H/1482/001/DC Applicant: Reckitt Benckiser Reference
More informationSafety Manual: DAD Trial
Safety Manual: DAD Trial Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial Short title: Diabetes and Depression
More informationCost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.
Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. The National Centre for Pharmacoeconomics (NCPE) has issued a
More informationBeurteilungsbericht zur Veröffentlichung. (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Poulvac IB Primer
Beurteilungsbericht zur Veröffentlichung (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) Zulassungsdatum: 06.03.2000 Zulassungsnummer: 167a/88 Datum der Erstellung des öffentlichen Beurteilungsberichts: 15.05.2013
More informationRegulatory Experience in Reviewing CV Safety for Diabetes
Regulatory Experience in Reviewing CV Safety for Diabetes Drugs Kristina Dunder MD, PhD, Alternate CHMP member MPA, Sweden Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationOverview of the PAHO strategy and activities to strengthen National Regulatory Authorities in the Americas
Overview of the PAHO strategy and activities to strengthen National Regulatory Authorities in the Americas Ma. de los Angeles Cortes Regional Advisor on Vaccines and Biologicals HSS/MT Annecy, France March
More informationLessons from Rotavirus Vaccine Implementation in the U.S.
Lessons from Rotavirus Vaccine Implementation in the U.S. Jeff Duchin, MD Chief, Communicable Disease Epidemiology & Immunization Section Public Health - Seattle & King County Professor in Medicine, Division
More informationUnderstanding Today s Probiotics Regulations in South East Asia. Wai Mun Poon Regulatory Affairs Consultant
Understanding Today s Probiotics Regulations in South East Asia Wai Mun Poon Regulatory Affairs Consultant waimun@wongsjasia.com Probiotic Foods in South East Asia More probiotic foods are being introduced
More informationResponding to Vaccine Safety Events
Responding to Vaccine Safety Events Karen Midthun, MD, Deputy Director Center for Biologics Evaluation and Research, FDA ICDRA Conference Berne, Switzerland September 19, 2008 1 Vision for CBER INNOVATIVE
More informationSCIENTIFIC DISCUSSION. London, Product name: Zostavax Procedure No. EMEA/H/C/000674/II/0003
SCIENTIFIC DISCUSSION London, 21.06.2007 Product name: Zostavax Procedure No. EMEA/H/C/000674/II/0003 SCIENTIFIC DISCUSSION 3.1. Introduction ZOSTAVAX is a live attenuated vaccine containing Varicella-zoster
More informationDiscovery of Potent, Highly Selective, Broad Spectrum Antivirals
Discovery of Potent, Highly Selective, Broad Spectrum Antivirals Fred Hutch/Merck Infectious Disease Summit May 10, 2018 Sam Lee, Ph.D. 1 Forward Looking Statements This presentation contains forward-looking
More informationEthics of Science and Technology Assessment 20. Functional Foods
Ethics of Science and Technology Assessment 20 Functional Foods Bearbeitet von R. Chadwick, S. Henson, B. Moseley, G. Koenen, M. Liakopoulos, C. Midden, A. Palou, G. Rechkemmer, D. Schröder, A. von Wright
More informationRegulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017
Regulation of Herbal and Traditional Medicines in Germany BfArM in Dialogue - TradReg 2017 Prof. Dr. Werner Knöss, Dr. Jacqueline Wiesner TradReg2017 Germany September 2017 Page 1 Federal Institute for
More informationFor information only: all participants in the graduated plan procedure. 7 January 2013
Paul-Ehrlich-Institut P.O. Box 63207 Langen, Germany To: All marketing authorisation holders of cellular blood products and therapeutic single plasma as well as holders of an authorisation for stem cells
More informationThe reassortants are propagated in Vero cells using standard tissue culture techniques in the absence of antifungal agents.
NEW ZEALAND DATA SHEET Name of Medicine RotaTeq rotavirus vaccine, live, oral, pentavalent Single dose 2 ml unit dosing tube Presentation RotaTeq is available as a single, pre-filled 2 ml unit dose in
More informationPublication output in the field of Public Health and its appreciation at political level in Austria
Eva Schwarz; Manfred Maier Publication output in the field of Public Health and its appreciation at political level in Austria 102 Innovation durch Evaluation: Impulse setzen durch Evaluationsprozesse
More informationNational Immunisation Programme changes Michael Baker. Wessex Public Health England Centre
National Immunisation Programme changes 2013-14 Michael Baker Wessex Public Health England Centre Changes to the Meningococcal serogroup C conjugate (MenC) vaccine schedule in 2013 2 Immunisation Programme
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Rotarix powder and solvent for oral suspension Rotavirus vaccine, live 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After reconstitution,
More informationCloudbreak. March Cidara Therapeutics
Cloudbreak March 2019 Cidara Therapeutics 2019 0 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAufklärung Nr. 27: Pneumokokken (Konjugat) Englisch / English
On protective immunization against pneumococcal diseases in infants/small children with conjugate vaccine Pneumococcal infections are caused by Streptococcus pneumoniae bacteria. There are more than 90
More informationU.S. Food & Drug Administration Center for Food Safety & Applied Nutrition Foodborne Pathogenic Microorganisms and Natural Toxins Handbook.
U.S. Food & Drug Administration Center for Food Safety & Applied Nutrition Foodborne Pathogenic Microorganisms and Natural Toxins Handbook Rotavirus 1. Name of the Organism: Rotavirus Rotaviruses are classified
More informationBeurteilungsbericht zur Veröffentlichung. (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) CIRBLOC. Zulassungsdatum:
Beurteilungsbericht zur Veröffentlichung (gemäß 31 Abs. 2 Tierimpfstoff-Verordnung) CIRBLOC Zulassungsdatum: 30.03.2017 Zulassungsnummer: PEI.V.11810.01.1 Datum der Erstellung des öffentlichen Beurteilungsberichts:
More informationAdverse Events Following. Kevin Connolly Waterford, Aug. 25, 2016
Adverse Events Following Immunisation Kevin Connolly Waterford, Aug. 25, 2016 Abbreviations ADR adverse drug reaction AE adverse event AEFI adverse event following immunisation SAE serious adverse event
More informationFoodborne viruses: the known unknowns. Martin D Agostino Virologist, Campden BRI 8 th June 2016
Foodborne viruses: the known unknowns Martin D Agostino Virologist, Campden BRI 8 th June 2016 What are Foodborne Viruses? Submicroscopic organisms No intrinsic metabolism Obligate parasites They cannot
More informationPUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT
PAUL-EHRLICH-INSTITUT Bundesamt für Sera und Impfstoffe Federal Agency for Sera and Vaccines Paul-Ehrlich-Strasse 51-59 63225 Langen Germany MUTUAL RECOGNITION PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT
More informationDARPA-BAA Frequently Asked Questions
DARPA-BAA-16-42 Frequently Asked Questions Last Updated: 7/19/2016 (Version 3) New Questions highlighted GENERAL INFORMATION Q: If my research is relevant in this field, but is not geared specifically
More information